Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Iloperidone - Vanda Pharmaceuticals

Next Previous
Drug Profile

Iloperidone - Vanda Pharmaceuticals

Alternative Names: Fanapt; Fanaptum; Fiapta; HP-873; ILO-522; VYV-683; Zomaril

Latest Information Update: 05 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer MegaPharm Ltd; Novartis; PROBIOMED; University of Colorado at Denver; Vanda Pharmaceuticals
  • Class Antipsychotics; Isoxazoles; Mood stabilisers; Piperidines; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 5-HT2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bipolar disorders; Schizophrenia
  • Phase II Post-traumatic stress disorders; Psychotic disorders
  • No development reported Unspecified

Most Recent Events

  • 31 Jul 2024 Launched for Bipolar disorders in USA (PO)
  • 31 Jul 2024 Vanda expects to initiate a Phase III trial for the long acting injectable (LAI) formulation of Fanapt® by the end of 2024
  • 09 May 2024 Vanda Pharmaceuticals plans a clinical trial programme for Depressive disorders

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top